

18 September 2023

Clarification on MOU with Temasek-linked InnoVentures to progress China expansion

Osteopore Limited (ASX: OSX; Osteopore or Company), a global company founded in Singapore and listed in Australia, seeks to provide the following clarifications pertaining to the release of our announcement on 12 September 2023 regarding the signing of a binding MOU with InnoVentures Inc (**InnoVentures**).

As previously announced, Osteopore has signed a MOU with Innoventures to enter into a joint venture (**JV**) with the purpose of commercialising Osteopore's orthopaedic products – including reconstruction, regenerative implant and bone defect products – in China.

It is anticipated that Osteopore's in-house developed high tibial osteotomy (HTO) implant – used in a surgical procedure that realigns the knee joint – will be the first product that the JV Co will seek regulatory approval for with the view of commercialising. While the JV is initially focused on orthopaedic applications of OSX products, the JV will have a right of first negotiation for Chinese rights for non-orthopaedic applications.

The Company wishes to withdraw the disclosure on the prospective investor relationship in the announcement dated 12 September 2023, as it is early to confirm any details on the relationship and there is no agreement at this stage.

The timeframe involved for seeking regulatory approval and commercialisation of Osteopore's high tibial osteotomy (**HTO**) implant, the first product that the JV will seek regulatory approval for with the view of commercialising, is approximately 2 – 4 years, subject to completeness of documentation, and meeting regulatory requirements. The financial impact that the JV will have on the Company cannot be assessed at this stage.

Osteopore will move towards executing a definitive agreement pertaining to the JV by 30 November 2023, and will provide further information concerning the definitive agreement when it has been executed.

ENDS

This announcement dated 18 September 2023 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

T: +65 9011 7009

E: mark_leong@osteopore.com

Isaac Stewart

Media & Investor Relations

Cannings Purple

T: +61 423 306 795

E: istewart@canningspurple.com.au

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time only to allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

About InnoVentures Inc

InnoVentures Inc is a China-based medical technology incubator and accelerator committed to supporting innovations with lasting value through integrating global innovation and talent. Enabling rapid development from concept through to prototype and device with its experienced multidisciplinary team, state-of-the-art facilities, best-in-class regulatory and commercialisation services, and deep capital networks.

The InnoVentures team has a proven track record in the medical technology space with leaders ranging from multinational company C-suites to entrepreneurs who have built successful medical device start-ups. With a diverse portfolio of companies, InnoVentures is adept at managing projects from the start-up phase through to commercialisation, and/or acquisition, having overseen a range of successful exits.



Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are or may be, forward-looking statements.

Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Depending on several factors, actual results may differ materially from those expressed or implied by these forward-looking statements.

